All In MedTech

Device Trial Radar · NCT00401466

Remote Follow-up of Patients Receiving Implantable Cardioverter Defibrillator for Prophylactic Therapy

Remote Follow-up for ICD-Therapy in Patients Meeting MADIT II Criteria (REFORM)

Last checked: Nov 20, 2026Latest source record: Jan 17, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 155 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

155

Actual

Start

Jan 2004

Primary completion

Jul 2008

Study completion Jul 2008

Sponsor

Lead sponsor
Biotronik SE & Co. KGNot on our public-company list
Sponsor type
Industry
First posted
Nov 20, 2006

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Health services research
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The completed MADIT II study has shown that implantation of a cardioverter-defibrillator (ICD) in patients with a reduced left ventricular ejection fraction and a prior myocardial infarction reduces death from any cause. The probability of the first therapy due to ventricular tachyarrhythmia was about 34% within 3 years. With a 3-month ICD-follow-up scheme, as it is in the standard ICD therapy, the majority of patients is followed more closely than necessary with respect to anti-tachyarrhythmia ICD therapy. A Home Monitoring (HM) function has been integrated into several ICD models from Biotronik (Berlin , Germany), for close remote monitoring of ICD patients. The HM function may substitute in-clinic follow-up controls. The objective of our study is to compare a standard 3-month follow-up scheme and a 12-month follow-up scheme using HM in ICD recipients with the "MADIT II indications". The comparison should be made with respect to the difference in follow-up burden and the associated costs, and regarding possible impact of the remote follow-up via HM on all cause mortality, hospitalization, and patients' quality of life.

Conditions

  • Ventricular Fibrillation
  • Ventricular Tachycardia

Interventions

  • Implantable Cardioverter DefibrillatorDevice

    ICD with Biotronik Home Monitoring capability

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of follow-up visitsTime frame: 27 months

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Institute of clinical and experimental medicine

    Prague, Czechia

  • Hospital Na Homolce

    Prague, Czechia

  • Zentralklinik Bad Berka

    Bad Berka, Germany

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.